Beyond antibiotic prescribing rates: first-line antibiotic selection, prescription duration, and associated factors for respiratory encounters in urgent care.

antibiotic selection antibiotic stewardship prescription duration respiratory tract infections urgent care

Journal

Antimicrobial stewardship & healthcare epidemiology : ASHE
ISSN: 2732-494X
Titre abrégé: Antimicrob Steward Healthc Epidemiol
Pays: England
ID NLM: 9918266096106676

Informations de publication

Date de publication:
2023
Historique:
received: 14 05 2023
revised: 03 07 2023
accepted: 09 07 2023
medline: 29 9 2023
pubmed: 29 9 2023
entrez: 29 9 2023
Statut: epublish

Résumé

Assess urgent care (UC) clinician prescribing practices and factors associated with first-line antibiotic selection and recommended duration of therapy for sinusitis, acute otitis media (AOM), and pharyngitis. Retrospective cohort study. All respiratory UC encounters and clinicians in the Intermountain Health (IH) network, July 1st, 2019-June 30th, 2020. Descriptive statistics were used to characterize first-line antibiotic selection rates and the duration of antibiotic prescriptions during pharyngitis, sinusitis, and AOM UC encounters. Patient and clinician characteristics were evaluated. System-specific guidelines recommended 5-10 days of penicillin, amoxicillin, or amoxicillin-clavulanate as first-line. Alternative therapies were recommended for penicillin allergy. Generalized estimating equation modeling was used to assess predictors of first-line antibiotic selection, prescription duration, and first-line antibiotic prescriptions for an appropriate duration. Among encounters in which an antibiotic was prescribed, the rate of first-line antibiotic selection was 75%, the recommended duration was 70%, and the rate of first-line antibiotic selection for the recommended duration was 53%. AOM was associated with the highest rate of first-line prescriptions (83%); sinusitis the lowest (69%). Pharyngitis was associated with the highest rate of prescriptions for the recommended duration (91%); AOM the lowest (51%). Penicillin allergy was the strongest predictor of non-first-line selection (OR = 0.02, 95% CI [0.02, 0.02]) and was also associated with extended duration prescriptions (OR = 0.87 [0.80, 0.95]). First-line antibiotic selection and duration for respiratory UC encounters varied by diagnosis and patient characteristics. These areas can serve as a focus for ongoing stewardship efforts.

Identifiants

pubmed: 37771738
doi: 10.1017/ash.2023.416
pii: S2732494X23004163
pmc: PMC10523551
doi:

Types de publication

Journal Article

Langues

eng

Pagination

e146

Informations de copyright

© The Author(s) 2023.

Références

Biometrics. 1986 Mar;42(1):121-30
pubmed: 3719049
Pediatr Infect Dis J. 2018 Dec;37(12):1255-1257
pubmed: 29570583
Infect Dis Ther. 2020 Sep;9(3):677-681
pubmed: 32661600
Am J Infect Control. 2023 May;51(5):520-526
pubmed: 35940256
Antimicrob Agents Chemother. 2018 Jul 27;62(8):
pubmed: 29967028
JAMA Pediatr. 2021 May 1;175(5):475-482
pubmed: 33683325
JAMA Netw Open. 2022 Mar 1;5(3):e222117
pubmed: 35285918
JAMA. 2017 Jul 4;318(1):82-83
pubmed: 28672303
Infect Control Hosp Epidemiol. 2018 Mar;39(3):307-315
pubmed: 29378672
Clin Infect Dis. 2020 Apr 10;70(8):1781-1787
pubmed: 31641768
Allergy. 2017 Sep;72(9):1288-1296
pubmed: 28370003
J Am Med Inform Assoc. 2016 Apr;23(e1):e108-12
pubmed: 26554427
Antimicrob Agents Chemother. 2019 Oct 22;63(11):
pubmed: 31548186
JAMA. 2019 Jan 15;321(2):188-199
pubmed: 30644987
Cochrane Database Syst Rev. 2010 Sep 08;(9):CD001095
pubmed: 20824827
N Engl J Med. 2019 Dec 12;381(24):2338-2351
pubmed: 31826341
J Pediatr. 2022 Jan;240:221-227.e9
pubmed: 34274307
Open Forum Infect Dis. 2021 Jun 17;8(7):ofab324
pubmed: 34631924
JAMA Intern Med. 2018 Jul 1;178(7):992-994
pubmed: 29582085
JAMA Intern Med. 2016 Dec 1;176(12):1870-1872
pubmed: 27775770
Am J Infect Control. 2021 Aug;49(8):1052-1057
pubmed: 33524451
Clin Infect Dis. 2018 Sep 28;67(8):1168-1174
pubmed: 29590355
JAMA Intern Med. 2018 Oct 1;178(10):1342-1349
pubmed: 30193357
Ann Allergy Asthma Immunol. 2010 Oct;105(4):259-273
pubmed: 20934625
JAMA. 2016 May 3;315(17):1864-73
pubmed: 27139059
JAMA Intern Med. 2018 Sep 1;178(9):1267-1269
pubmed: 30014128
Clin Infect Dis. 2021 Jan 23;72(1):133-137
pubmed: 32484505
JAMA Netw Open. 2023 May 1;6(5):e2313011
pubmed: 37166794
Pediatrics. 2019 Feb;143(2):
pubmed: 30622156
Ann Intern Med. 2020 Feb 18;172(4):240-247
pubmed: 32016285
Open Forum Infect Dis. 2016 Aug 10;3(3):ofw168
pubmed: 27704022
J Pediatr. 2020 May;220:109-115.e1
pubmed: 32111379
Clin Infect Dis. 2021 May 18;72(10):e663-e666
pubmed: 32936884
Pediatrics. 2022 Dec 1;150(6):
pubmed: 36377382
Pediatr Infect Dis J. 2000 Apr;19(4):354-5
pubmed: 10783029
Intern Med J. 2017 Nov;47(11):1292-1297
pubmed: 28742226
JAMA. 2001 Oct 17;286(15):1849-56
pubmed: 11597286
Pediatrics. 2022 Jul 1;150(1):
pubmed: 35703030

Auteurs

Allan M Seibert (AM)

Division of Infectious Diseases, Intermountain Health, Salt Lake City, UT, USA.

Carly Schenk (C)

Maine Medical Center, Portland, ME, USA.

Whitney R Buckel (WR)

Pharmacy Services, Intermountain Health, Salt Lake City, UT, USA.

Payal K Patel (PK)

Division of Infectious Diseases, Intermountain Health, Salt Lake City, UT, USA.

Nora Fino (N)

Division of Epidemiology, Department of Internal Medicine, University of Utah, Salt Lake City, UT, USA.

Valoree Stanfield (V)

Office of Patient Experience, Intermountain Health, Salt Lake City, UT, USA.

Adam L Hersh (AL)

Department of Pediatrics, Division of Infectious Diseases, University of Utah School of Medicine, Salt Lake City, UT, USA.

Eddie Stenehjem (E)

Division of Infectious Diseases, Intermountain Health, Salt Lake City, UT, USA.

Classifications MeSH